The use of tenofovir as part of a HAART regimen has been widely used in HIV-multi-experienced-patients because of its favourable resistance profile. Tenofovir is mainly eliminated by the kidneys and renal toxicity should be carefully monitored. We describe here the case of an HIV-infected patient, without a prior history of renal failure who developed nephrolithiasis and hydronephrosis after starting a tenofovir-containing HAART regimen.
|Titolo:||Nephrolithiasis and hydronephrosis in an HIV-infected man receiving tenofovir|
|Autori interni:||D'ARMINIO MONFORTE, ANTONELLA (Penultimo)|
|Settore Scientifico Disciplinare:||Settore MED/17 - Malattie Infettive|
|Data di pubblicazione:||2004|
|Appare nelle tipologie:||01 - Articolo su periodico|